Multiple breath washout (MBW) testing using sulfur hexafluoride: reference values and influence of anthropometric parameters.
respiratory measurement
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
27
02
2020
revised:
07
01
2021
accepted:
20
01
2021
pubmed:
18
2
2021
medline:
10
7
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
Multiple breath washout (MBW) using sulfur hexafluoride (SF We evaluated cross-sectional data from 100 pulmonary healthy never-smokers and smokers (mean 51 (SD 20), range 20-88 years). Lung clearance index (LCI), acinar (S Age was the only meaningful parameter influencing SF SF NCT04099225.
Sections du résumé
BACKGROUND
Multiple breath washout (MBW) using sulfur hexafluoride (SF
METHODS
We evaluated cross-sectional data from 100 pulmonary healthy never-smokers and smokers (mean 51 (SD 20), range 20-88 years). Lung clearance index (LCI), acinar (S
RESULTS
Age was the only meaningful parameter influencing SF
CONCLUSION
SF
TRIAL REGISTRATION NUMBER
NCT04099225.
Identifiants
pubmed: 33593931
pii: thoraxjnl-2020-214717
doi: 10.1136/thoraxjnl-2020-214717
doi:
Substances chimiques
Sulfur Hexafluoride
WS7LR3I1D6
Banques de données
ClinicalTrials.gov
['NCT04099225']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-386Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The following financial activities outside the submitted work exist: FT received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA, as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Roche, Novartis and Sanofi-Aventis. JoS received travel support and speaker fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche. MB received speaker or consultation fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Impulse Dynamics and Zoll Medical. IA received travel support as well as speaker or consultation fees from Abiomed, Bayer, Boehringer Ingelheim and St Jude Medical.